Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 7/20 | 0.43 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313476 | 0.92 | MAPKAPK2 (0.46) | CDC7DYRK1ACLK2CLK3SYK | |
| SCHEMBL6312651 | 0.89 | CDC7 (0.47) | CDC7DYRK1ACLK2SYKWEE1 | |
| SCHEMBL6321411 | 0.87 | NPC1 (0.49) | DYRK1ACLK2CLK3SYKIGF1R | |
| SCHEMBL6311247 | 0.85 | CDK1 (0.50) | DYRK1ACLK2CLK3SYKCDK2 | |
| SCHEMBL6315305 | 0.82 | DYRK1A (0.45) | DYRK1ACLK2CLK3SYKEGFR | |
| SCHEMBL6312020 | 0.81 | SYK (0.47) | DYRK1ACLK2CLK3SYKIGF1R | |
| SCHEMBL6313590 | 0.81 | CDC7 (0.47) | CDC7DYRK1ACLK2SYKWEE1 | |
| SCHEMBL6311534 | 0.80 | NPC1 (0.46) | DYRK1ACLK2CLK3SYKCDK2 | |
| SCHEMBL6314056 | 0.79 | IGF1R (0.52) | DYRK1ACLK2CLK3SYKCDK2 | |
| SCHEMBL6319822 | 0.78 | IGF1R (0.50) | DYRK1ACLK2CLK3SYKCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | CDC7 2635/4885DYRK1A 2642/4885CLK2 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.